IL136460A0 - Molecular dispersion composition with enhanced bioavailability - Google Patents

Molecular dispersion composition with enhanced bioavailability

Info

Publication number
IL136460A0
IL136460A0 IL13646098A IL13646098A IL136460A0 IL 136460 A0 IL136460 A0 IL 136460A0 IL 13646098 A IL13646098 A IL 13646098A IL 13646098 A IL13646098 A IL 13646098A IL 136460 A0 IL136460 A0 IL 136460A0
Authority
IL
Israel
Prior art keywords
dispersion composition
molecular dispersion
enhanced bioavailability
bioavailability
enhanced
Prior art date
Application number
IL13646098A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL136460A0 publication Critical patent/IL136460A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13646098A 1997-12-22 1998-12-17 Molecular dispersion composition with enhanced bioavailability IL136460A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99716897A 1997-12-22 1997-12-22
PCT/US1998/026218 WO1999032118A1 (en) 1997-12-22 1998-12-17 Molecular dispersion composition with enhanced bioavailability

Publications (1)

Publication Number Publication Date
IL136460A0 true IL136460A0 (en) 2001-06-14

Family

ID=25543717

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13646098A IL136460A0 (en) 1997-12-22 1998-12-17 Molecular dispersion composition with enhanced bioavailability

Country Status (27)

Country Link
EP (1) EP1039908B1 (cs)
JP (2) JP2001526227A (cs)
KR (1) KR100597331B1 (cs)
CN (1) CN1116039C (cs)
AR (1) AR017436A1 (cs)
AT (1) ATE260105T1 (cs)
AU (1) AU761994C (cs)
BR (1) BR9813728A (cs)
CA (1) CA2315685C (cs)
CO (1) CO4970793A1 (cs)
CZ (1) CZ295956B6 (cs)
DE (1) DE69821984T2 (cs)
DK (1) DK1039908T3 (cs)
ES (1) ES2214757T3 (cs)
HU (1) HU229052B1 (cs)
ID (1) ID28304A (cs)
IL (1) IL136460A0 (cs)
MY (1) MY126580A (cs)
NO (1) NO327383B1 (cs)
NZ (1) NZ504834A (cs)
PE (1) PE20000012A1 (cs)
PL (1) PL192423B1 (cs)
PT (1) PT1039908E (cs)
SK (1) SK285662B6 (cs)
TW (1) TW527196B (cs)
WO (1) WO1999032118A1 (cs)
ZA (1) ZA9811592B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
MXPA04008536A (es) * 2002-03-04 2005-09-08 Teva Pharma Forma de dosificacion de liberacion controlada.
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PT103661B (pt) 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
EP0214092A1 (en) * 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
WO1993011749A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company A process for the preparation of a solid dispersion
JPH0848632A (ja) * 1994-08-08 1996-02-20 Kanebo Ltd エトポシドを含有する固形組成物および固形製剤
AR005152A1 (es) * 1995-12-22 1999-04-14 Schering Corp Amidas tricíclicas útiles para la inhibición de la función de la proteina-g, sus sales , una composición farmacéutica que las contienen y el uso de las mismas para la fabricación de un medicamento para el tratamiento de enfermedades proliferativas
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit

Also Published As

Publication number Publication date
KR100597331B1 (ko) 2006-07-10
JP2010059212A (ja) 2010-03-18
HK1027040A1 (en) 2001-01-05
CO4970793A1 (es) 2000-11-07
TW527196B (en) 2003-04-11
PT1039908E (pt) 2004-06-30
CA2315685C (en) 2008-02-05
DE69821984T2 (de) 2004-12-30
HU229052B1 (en) 2013-07-29
PE20000012A1 (es) 2000-01-18
AU761994C (en) 2004-01-08
ATE260105T1 (de) 2004-03-15
SK8962000A3 (en) 2001-07-10
NO327383B1 (no) 2009-06-22
PL341344A1 (en) 2001-04-09
AU761994B2 (en) 2003-06-12
HUP0100850A2 (hu) 2001-10-28
NO20003235L (no) 2000-07-27
JP2001526227A (ja) 2001-12-18
NZ504834A (en) 2001-12-21
ID28304A (id) 2001-05-10
KR20010033397A (ko) 2001-04-25
CA2315685A1 (en) 1999-07-01
ES2214757T3 (es) 2004-09-16
NO20003235D0 (no) 2000-06-21
SK285662B6 (sk) 2007-05-03
DE69821984D1 (de) 2004-04-01
CZ20002304A3 (cs) 2001-04-11
AU1814399A (en) 1999-07-12
EP1039908A1 (en) 2000-10-04
CN1282245A (zh) 2001-01-31
CZ295956B6 (cs) 2005-12-14
WO1999032118A1 (en) 1999-07-01
AR017436A1 (es) 2001-09-05
CN1116039C (zh) 2003-07-30
EP1039908B1 (en) 2004-02-25
PL192423B1 (pl) 2006-10-31
ZA9811592B (en) 1999-06-17
HUP0100850A3 (en) 2002-12-28
MY126580A (en) 2006-10-31
BR9813728A (pt) 2000-10-10
DK1039908T3 (da) 2004-05-03

Similar Documents

Publication Publication Date Title
HUP0101532A3 (en) Improved interferon polymer conjugates
HUP0000660A3 (en) Epoxy-polysiloxane polymer composition
IL124819A0 (en) Polymer compositions
ZA983899B (en) Polymer compositions
HUP0100850A3 (en) Molecular dispersion composition with enhanced bioavailability
GB9805693D0 (en) Polymeric composition
GB9800685D0 (en) Polymer composition
SG77209A1 (en) Polymer
GB2329182B (en) Polymer blend
GB9716454D0 (en) Polymer
GB2327904B (en) Polymer composites
ZA9810472B (en) An antimalarial composition
GB2325893B (en) Folders
ZA974338B (en) Anitfungal compositions with improved bioavailability
GB9716375D0 (en) Polymer composition
HU9700170V0 (en) Multi purpose shoe-last
AUPO482297A0 (en) Extending property post
GB9701813D0 (en) Polymers
GB9712744D0 (en) Polymers
GB9720250D0 (en) Polymers
GB9727134D0 (en) Polymers
HUP0000866A3 (en) Polymers
ZA983923B (en) Biofuncational polymers
GB9718133D0 (en) Polymers
GB9718909D0 (en) Polymers

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees